Institutional shares held 82.3 Million
26.1K calls
11.8K puts
Total value of holdings $2.75B
$871K calls
$394K puts
Market Cap $1.79B
53,752,800 Shares Out.
Institutional ownership 153.19%
# of Institutions 252


Latest Institutional Activity in CRNX

Top Purchases

Q1 2025
Rhumbline Advisers Shares Held: 132K ($4.41M)
Q1 2025
Xponance, Inc. Shares Held: 6.86K ($229K)
Q1 2025
Amalgamated Bank Shares Held: 3.16K ($105K)
Q1 2025
Arizona State Retirement System Shares Held: 23.9K ($798K)
Q1 2025
Gf Fund Management Co. Ltd. Shares Held: 2.38K ($79.3K)

Top Sells

Q1 2025
Victory Capital Management Inc Shares Held: 251K ($8.39M)
Q1 2025
Sg Americas Securities, LLC Shares Held: 522K ($17.4M)
Q1 2025
New York State Common Retirement Fund Shares Held: 138K ($4.61M)
Q1 2025
Alps Advisors Inc Shares Held: 67.3K ($2.25M)
Q1 2025
Hennion & Walsh Asset Management, Inc. Shares Held: 32.6K ($1.09M)

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.


Insider Transactions at CRNX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
703K Shares
From 18 Insiders
Grant, award, or other acquisition 294K shares
Exercise of conversion of derivative security 409K shares
Sell / Disposition
393K Shares
From 6 Insiders
Open market or private sale 393K shares

Track Institutional and Insider Activities on CRNX

Follow Crinetics Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if
Any

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX